Kornimate/medical-research-clean huggingface dataset:
the effect of telehealth ontario on non-urgent emergency department use at the hospital for sick children

Conditions: Emergency Department Visit

Summary: the purpose of this study is to compare the rate of non-urgent emergency department use between three groups of patients: those who were referred to the emergency department by telehealth ontario; those who were referred by a physician; and those who arrived without being advised by a nurse or a doctor.

some studies have shown that certain telephone nursing advice lines are effective in reducing non-urgent emergency department use. however, to my knowledge, no study has investigated the efficacy of telehealth ontario in particular. there are important differences between telehealth ontario and other phone lines that have been evaluated, in terms of the method in which calls are handled, the diversity of the population served, and the place of the phone-in line within the health care system. these studies, the results of which cannot be extrapolated directly to telehealth ontario, should not replace the direct study of the impact and utility of telehealth ontario. currently telehealth ontario receives over 3000 calls daily from residents of ontario who are concerned about their health. these callers rely on the advise of telehealth nurses to direct the care they seek out for themselves and for their families. the provincial government also relies on telehealth ontario - to provide a useful service within the health care system, relieving the pressure on over-crowded emergency departments by directing patients with non-urgent medical complaints to more appropriate avenues of treatment. this will be the first study to examine the impact of telehealth ontario. although only a small aspect of telehealth's impact will be examined - the impact on non-urgent emergency department use at sick kids - it is an important first step. the results of this study may serve to guide modifications to telehealth that will make it more accessible to specific groups within the community, more reliable in the advice it provides, and more effective in delivering its message to callers.

Eligibility criteria:
inclusion criteria: all children presenting to the ed between 0600 and 2400 during the study period exclusion criteria: 1. children arriving without an adult, as consent could not be obtained. 2. children with whose parents communication was not possible in english, as it was not possible to provide translation services for this study. 3. children arriving by direct transfer from another hospital. 4. children arriving by ambulance summoned by someone other than the parent or guardian. 5. children arriving at the ed for a pre-arranged visit/appointment. 6. children requiring immediate resuscitation.

Keywords: emergency department visit telehealth ontario triage levels
the role of quantitative measures on dual-energy ct in the prediction of colorectal adenocarcinoma

Conditions: Colorectal Adenocarcinoma

Summary: to demonstrate the potential role of dual-energy computed tomography (dect) by iodine maps data, aimed at discriminating colon cancer from colon wall pseudo-thickening.

prospectively, 50 consecutive patients with pathology-proved colorectal tumor (detected by optical colonoscopy) who undergo routine thoraco-abdominal dect for initial staging in the department of radiology at our institution from april 2020, will be included. the exclusion criteria are as follows: patients with body mass index (bmi) above 30 kg/m2, patients with renal insufficiency (estimated glomerular filtration rate \< 30 ml/min), allergy to iodinated contrast and a known history of previous abdominal radiotherapy. all patients will undergo a staging enhanced thoraco-abdominal ct by 256-slices cts (revolution ct, ge healthcare) at fribourg hospital. dects will be acquired without an enema, rectal insufflation or oral contrast to have collapsed colorectal wall for further measurements and to simulate routine clinical practice. no additional screening procedures, such as a laboratory or diagnostic tests are necessary for the present study. upon acquiring 50 patients, ct quantitative assessments will be performed. initially, data will be transferred to aw advantage workstations (ge healthcare). thereafter, for each patient, the iodine map images will be created by post-processing by. all ct quantitative measurements will be performed independently by two radiologists. three regions of interest (roi) will be applied to colorectal tumor and the normal collapsed colorectal wall (confirmed previously by colonoscopy) and consequently, the mean of these measurements will be reported. these measurements correspond to mean iodine uptake of colorectal tumor and normal collapsed wall, respectively. finally, the iodine uptake of the tumoral lesion and normal collapsed wall in each patient will be compared to demonstrate the significant difference in iodine uptake. investigators anticipate that the obtained cut-off value will be a new benchmark in clinical practice, to exclude the colorectal tumors on non-prepared collapsed colon wall and eliminate the need for a complementary colonoscopy.

Eligibility criteria:
inclusion criteria: . pathology-proved colorectal tumor exclusion criteria: * bmi above 30 kg/m2 * renal insufficiency (estimated glomerular filtration rate \< 30 ml/min), * allergy to iodinated contrast, and a * known history of previous abdominal radiotherapy
effect of fish oil on plasma triglycerides in adults

Conditions: Hypertriglyceridemia

Summary: the purpose of this small, short pilot study is to determine the feasibility (e.g., recruitment, dose acceptance, retention) of a future longer trial comparing the effects of two types of omega-3 fats from fish oil on plasma triglycerides. the two types of fish oil are composed of (1) omega-3 fatty acids in triglyceride form; and (2) as esterified free fatty acids (i.e. ethyl esters). although these two types of fish oil supplements are available to the public, it remains unclear whether they are equally effective in lowering plasma triglycerides.

this study is a double-blinded, parallel design, placebo controlled trial with three active treatment arms to compare the triglyceride (tg) lowering effects of the same dose of epa and dha provided in three formulations of supplements that differ in the proportion of omega-3 fa present as ethyl esters vs. triglycerides. the active therapy for each of the three fish oil supplementation arms is 4 g/day of combined epa and dha provided as: a) 90% tg formulation, b) 60% tg formulation, or c) ethyl esters (esterified fatty acids)(i.e., 0% tg). the placebo was a soy oil supplement with an identical total fat content. the primary outcome is the 12-week change in tg concentrations in the active groups vs. placebo. secondary outcomes include ldl particle distribution, defined as either subclasses ldl1, ldl2, ldl3 and ldl4, and ldl subclass phenotype patterns a, b, or a/b.

Eligibility criteria:
inclusion criteria:\*gender: both women and men * age: \> or = 18 years * ethnicity and race: all ethnic and racial backgrounds welcome * fasting blood triglycerides greater than or equal to 150 mg/dl * planning to be available for clinic visits for the 12 weeks of study participation * ability and willingness to give written informed consent * no known active psychiatric illness. exclusion criteria:\*at screening: * daily intake of dietary supplements containing omega-3 fas within the past month. * fasting blood glucose greater than or equal to 126 mg/dl * self reported personal history of: * clinically significant atherosclerosis (e.g., cad, pad) * malignant neoplasm * subjects currently receiving the following medications (self report): * lipid lowering drugs including statins * anti-hypertensive drugs: beta-blockers and thiazides * body mass index (bmi) greater than or equal to 40. * pregnant or lactating * inability to communicate effectively with study personnel

Keywords: fish oil triglycerides low-density lipoprotein (ldl) cholesterol low-density lipoprotein (ldl) subclass low-density lipoprotein (ldl) particle size low-density lipoprotein (ldl) phenotype
iatrogenic withdrawal symptoms in severe traumatic brain injury

Conditions: Iatrogenic Withdrawal Symptomes

Summary: iatrogenic withdrawal symptomes has been associated with prolonged mechanical ventilation and the and the derived symptoms such as fever and agitation has been shown to cause significantly prolonged icu and hospital length of stay. the incidence of iws in the adult general icu ranges from 16,7-55%. to this date, the incidence of iws has not been studied in patients with tbi.


Eligibility criteria:
inclusion criteria: * adult patients suffering from severe tbi and were mechanical ventilated and received continuous infusions of opioids, benzodiazepines and neuromuscular blocking agents for 72ours or more exclusion criteria: * age \<18 years, patients who died before discharge, chronic alcohol abuse, regular use of heroin, cocaine and amphetamines, chronic use of opioids, patient that were primary admitted to other icus and patients that were moved to other icus with ongoing infusions.
comparison of a tacrolimus hexal® based regimen versus a prograf® based regimen in de novo renal transplant recipients

Conditions: Pharmacokinetics Study in de Novo Kidney Transplantation

Summary: the purpose of this study was to investigate if tacrolimus hexal® has similar pharmacokinetic properties compared to prograf® in de novo renal transplant patients and whether the comparable exposure resulted in similar renal function.

in phase ii of this study there was a high patient drop-out rate and an associated long recruitment timespan. eighty-one patients were recruited to phase i and only 45 of the required 54 patients were available for pk analysis. to complete phase ii, 245 (in addition to 81) patients were to be required to achieve calculated sample size. therefore the protocol was amended to stop recruitment and analyze phase i patient data of cerl080ade27 (pk-phase i). patients that were still ongoing were scheduled for an end of study (eos) visit. during this visit patients were informed by the investigator about the end of study and advised about further treatment course.

Eligibility criteria:
inclusion: primary or sec. kidney transplanted patiens, written consent, cold ischemia \< 24 h exclusion: multi organ, immunological risc pts., pra \>20%, antibodys against hla-type of donor organ, hypersensitivity against tacro or mmf, other protocol-defined inclusion/exclusion criteria may apply

Keywords: pharmacokinetics study tacroliums gfr kidney transplant rejection allograft rejection xenograft rejection host vs graft disease renal transplant
validation of the measurement accuracy of the tcore thermometer

Conditions: Temperature Change, Body

Summary: the aim of the study conducted at the uksh is to investigate the measuring accuracy of the body core temperature thermometer tcore®. therefore the bias of the measurements to the reference measurements of the bladder catheter thermometer is determined.

the aim of the study conducted at the uksh is to investigate the measuring accuracy of the body core temperature thermometer tcore®. therefore the bias of the measurements to the reference measurements of the bladder catheter thermometer is determined. patients included are in the icu of the uksh and awake. they already have the reference thermometer in the catheter. the patient investigation time is limited to maximum 2 hours, saes will be recorded for 24 hours. the temperature of the two temperature sensors will be compared on three timepoints.

Eligibility criteria:
inclusion criteria: * body temperature \> 34 °c * signed consent * bladder catheter with temperature sensor exclusion criteria: * inflammation of the frontal sinus or the measuring point of the reference measurement (bladder) * skin irritation to the adhesive or other materials used * medication that locally affects the body temperature or the temperature of the reference body site (barbiturates, thyroid preparations, antipsychotics, new vaccines, aspirin, acetaminophen, ibuprofen, or similar) * taking antipyretics in the last 120 minutes before measurement
comparison of nn5401 plus insulin aspart with insulin detemir plus insulin aspart in type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in europe, oceania, and the united states of america (usa). the aim of this clinical trial is to compare nn5401 (insulin degludec/insulin aspart (idegasp)) with insulin detemir (idet) plus insulin aspart in patients with type 1 diabetes (main period) followed by the extension period comparing the long-term safety of nn5401 plus insulin aspart with insulin detemir plus insulin aspart. the main period is registered internally at novo nordisk as nn5401-3594 while the extension period is registered as nn5401-3645.


Eligibility criteria:
inclusion criteria: * for the main trial, nn5401-3594: * type 1 diabetes mellitus for at least 12 months * ongoing daily treatment with insulin (in a basal bolus regimen, premix insulin regimen, self mix regimen) for at least 12 months * hba1c 7.0-10.0% (both inclusive) * bmi (body mass index) below or equal to 35.0 kg/m\^2 * for the extension trial, nn5401-3645: * the subject must have completed the six-month treatment period in trial nn5401-3594 exclusion criteria: * for the main trial, nn5401-3594: * treatment with other insulin regimens than insulin in a basal bolus regimen/premix insulin regimen/self mix regimen within 3 months * cardiovascular disease within the last 6 months * uncontrolled treated/untreated severe hypertension * pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements * cancer and medical history of cancer * for the extension trial, nn5401-3645: * anticipated significant lifestyle changes during the trial * pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures
multivirus-specific t cells in the treatment of refractory cmv and/or ebv infection after allo-hsct

Conditions: CMV Infection; EBV Infection; Stem Cell Transplant

Summary: to evaluate the safety and tolerability of partial hla-matched vsts against both cmv and ebv viruses in recipients of allogeneic hematopoietic stem cells with refractory viral infections (cmv and/or ebv). preliminary evaluation of the efficacy of partial hla-matched vsts against both cmv and ebv viruses in recipients of allogeneic hematopoietic stem cells with refractory viral infections (cmv and/or ebv); to monitor the duration and expansion of multi-virus vsts cells after infusion.

this study consists of two parts: (1) the first stage is the safety evaluation of multi-virus vsts and the exploration of dlt and mtd; (2) the second phase is to evaluate the safety and efficacy of multi-viral vsts in selecting appropriate doses in the first phase.

Eligibility criteria:
inclusion criteria: * age ≥18 years old, and less than or equal to 70 years old, gender is not limited. * prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplantation. * persistent infection with cmv and/or ebv persists despite standard treatment . * prednisone or its equivalent hormone is less than or equal to 0.5 mg/kg/ day when enrolled. * ecog score ≤3, expected survival greater than 3 months. * end blood oxygen saturation ≥90% on room air. * available multi-virus-specific cytotoxic t lymphocytes. * negative pregnancy test in female patients if applicable. * written informed consent and/or signed assent line from patient, parent or guardian. exclusion criteria: * within 28 days after allogeneic hematopoietic stem cell transplantation. * active iii-iv acute gvhd, and/or moderate and above chronic gvhd. * severe organ dysfunction: heart: new york heart association (nyha) levels iii and iv; liver: total bilirubin\>34umol/l; alt, ast\>2 times the normal upper limit; kidney: blood creatinine \>130umol/l; lung: type i or ii respiratory failure; brain: unconsciousness, intracranial hypertension. * received dli, other ctl, car-t, nk and other cell therapies, t cell monoclonal antibody immunosuppressants, or participated in any other clinical research related to drugs and medical devices within 28 days before enrollment. * poor compliance, and subjects deemed unsuitable for study participation by the investigator.

Keywords: cytomegalovirus epstein barr virus multivirus-specific cytotoxic t-lymphocytes stem cell transplant
multifidus activation, pain and functional disability in individuals with chronic low back pain

Conditions: Chronic Low Back Pain

Summary: chronic mechanical low back pain (cmlbp) is a common disabling health problem among the general population. multifidus muscle inhibition accompanying cmlbp plays a major role in perpetuating the pain and functional disability. lumbar stabilisation and treadmill exercises are established treatments for cmlbp. however, it is not known which of the two techniques is more effective. this study was conducted to compare the effects of lumbar stabilisation and treadmill walk on multifidus activation, pain and functional disability in individuals with cmlbp.

fifty-three individuals (23 females and 30 males) with cmlbp participated in this single blind randomised clinical trial. consecutive participants were recruited from the outpatient physiotherapy clinic of the aminu kano teaching hospital, kano, nigeria and were randomly assigned to one of two exercise groups: lumbar stabilisation group (lsg; n = 27) or treadmill walk group (twg; n = 26). however, 50 participants, (lsg: n = 25; and twg: n = 25) completed the eight week study. participants in the lsg had lumbar stabilisation exercises using mcgill protocol while those in the twg had walking exercise on a treadmill using the bruce protocol. treatment was applied three times weekly for eight weeks. outcomes assessed at baseline and end of eighth week of study were: pain intensity (pi) using visual analogue scale, functional disability (fd) using oswestry disability index questionnaire; and multifidus muscle activation (mma) level using a surface electromyography machine. data were analysed using descriptive statistics, paired and independent t-tests at α0.05.

Eligibility criteria:
inclusion criteria: 1. participants diagnosed with lbp of mechanical origin and have been present for 3 months or more. 2. participants who have a score of at least 20% on modified oswestry dis¬ability index (odi). 3. participants who gave consent to participate in the study. 4. participants who can comprehend instructions in english or hausa 5. participants who are not involved in any other form of exercise training during the course of the study. exclusion criteria: 1. patients with history of a prior surgery to the lumbosacral spine. 2. patients with any neurological findings indicating radiculopathy. 3. patients with very acute symptoms of lbp. 4. patients with evidence of systemic disease, carcinoma or organ diseases. 5. patients with obesity which due to reduce fatty infiltration that might affect electrical conductivity in the multifidus muscle. 6. patients below 18 years of age.

Keywords: lumbar stabilisation exercise treadmill walk multifidus muscle activation pain intensity functional disability
effects of therapeutic play on anxiety and fear

Conditions: Pediatric Cancer

Summary: this study was carried out as a randomized controlled experimental study in order to evaluate the effect of therapeutic game use on anxiety and fear levels before indwelling catheter intervention in children aged 6-12 years followed in the hematology oncology service. a simple randomization method was used to assign children to groups. ethics committee and institutional permission was obtained for the research. research data were obtained from a total of 80 children, 40 interventions and 40 controls, hospitalized in istanbul medical faculty pediatric hematology service between october 2022 and august 2023. data; it was evaluated with the information form, child follow-up form, child anxiety scale- state (ças-d) and child fear scale (ccs). for those assigned to the intervention group among the mother and child who signed the informed consent form; before the indwelling catheter intervention, the children were shown the procedure on the amigrumi knitted baby developed by the researcher, the catheter application area was explained through the cardiovascular image and the catheter to be inserted was shown as an example. for those assigned to the control group; no intervention was applied other than the hospital\&#39;s normal procedure. data were evaluated using the spps 26 (ibm corp. ibm 1989, 2019. spss statistics for windows, version 26.0. armonk, ny: ibm corp.) package program. it was determined that the mcq and ças-d scores of the children in the intervention group were significantly lower than those in the control group (p˂0.01). it was determined that the mean cta and respiratory rate of the children in the intervention group just before and 2 hours after the application were lower than the control group (p\&lt;0.001). according to the results of the research, it was determined that the therapeutic game applied before indwelling catheter intervention in children between the ages of 6-12 was effective in reducing children's anxiety and fear.

according to the results of the research, it was determined that the therapeutic game applied before indwelling catheter intervention in children between the ages of 6-12 was effective in reducing children's anxiety and fear.

Eligibility criteria:
inclusion criteria: * being between the ages of 6-12 being diagnosed with cancer receiving chemotherapy treatment it will be the first time that a permanent catheter will be inserted. exclusion criteria: * being in the terminal period hearing and/or visual impairment having another health problem or condition that will prevent communication (turkish inability to speak...etc)
screen-hfl (screening evaluation of the evolution of new heart failure) - a longitudinal study

Conditions: Heart Failure

Summary: heart failure (when the heart does not pump as well as it used to) is a medical condition which reduces the quality of life for the sufferers. approximately 10% of people in western societies aged over 75 develop heart failure. there has been a shift towards prevention of this disease and it is hoped that bnp (brain natriuretic peptides) and nt-probnp (n-terminal probnp) will prove to be useful indicators of those at greatest risk. the current study therefore plans to follow up the 3500 participants at risk of heart failure from the original screen-hf study. participants who are willing to participate will be contacted annually. they will undergo a short physical exam, will be asked to complete a quality of life questionnaire and will have a blood sample taken. at the end of the study participants will also have an ecg and an echocardiogram.


Eligibility criteria:
inclusion criteria: 1. consented and enrolled in the screen-hf study and who agreed to further contact 2. age ≥ 60 years 3. subjects at high-risk of subsequent development of heart failure; comprising at least one of: * prior myocardial infarction (mi) without known left ventricular (lv) dysfunction * current active ischaemic heart disease * prior cerebrovascular accident (cva) * known valvular heart disease without known lv dysfunction * atrial fibrillation * treated hypertension, of at least 2 years duration * treated diabetes mellitus, of at least 2 years duration * chronic renal impairment (egfr \< 60 ml/min) exclusion criteria: 1. known systolic or diastolic heart failure 2. lv systolic or diastolic dysfunction on echocardiography or other objective imaging modality (if known).

Keywords: heart failure bnp nt-probnp